Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

https://www.fosunpharma.com/en/

Latest From Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.

Artificial Intelligence China

The Shifting Sands Of Biopharma R&D

A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.

Companies Clinical Trials

Radionuclide Therapy Developers Attract Investor Attention in March China Fundraising

China's Chengdu New Radiomedicine Technology and the radiotherapy CRDMO Mitro Biotech bagged a combined $94m in their respective new financing rounds during March. Meanwhile, Beijing Varnotech Biopharm secured $83m for its vaccine candidates for the prevention of herpes zoster and respiratory syncytial virus infections. 

China Financing

CARSgen Wins China’s Fifth CAR-T Approval But Pricing Dilemma Unresolved

As China’s fifth approved CAR-T cell therapy, CARSgen/Huadong’s zevorcabtagene autoleucel is priced at $159,735 for a single infusion. Expanding patient access will become a formidable task for the companies, due to the poor prospects of reimbursement coverage by China’s public medical insurance program. 

China Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Ahon Pharmaceutical Co., Ltd.
    • Fosun Kite Biotechnology Co., Ltd.
    • Fosun Pharma Kite Biotechnology Co. Ltd.
    • Guilin Pharma
    • Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.
    • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    • Shenyang Hongqi Pharmaceuticals Co., Ltd.,
    • Fosun Industrial Co., Limited
UsernamePublicRestriction

Register